Activation of these pathways suggests that RAD51 may promote cancer cell proliferation and survival by driving the cell cycle, whereas concurrently participating in DNA repair mechanisms—including mismatch repair, the Fanconi anaemia pathway and homologous recombination—to maintain genomic stability and foster chemotherapy resistance. This evidence concerns the gene RAD51 and cancer.